Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23379292 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2
Condition: Moderate to Severe Glabellar Frown Lines
Interventions: Drug: IncobotulinumtoxinA (Xeomin) (20 Units);   Drug: Placebo

Indicates status has not been verified in more than two years